3
It also slows gastrointestinal motility, meaning that gastric (stomach) emptying is slowed down, and food will move through the GI tract more slowly
Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that orforglipron will prove to be a safe and effective treatment for obesity or overweight, that orforglipron will receive regulatory approval, or that Lilly will execute its strategy as expected
doi: 10.1016/j.clinre.2016.11.009 Summary Keywords glucagon-like peptide-1 receptor agonists, metabolic disease, metabolic dysfunction-associated steatotic liver disease, public health, umbrella review Citation Wu H, Zhang Z-H, Ye T, Chen J-N, Tung T-H and Zhu J-S (2026) Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review
demonstrated that although high dose exenatide treatment did not exercise a significant effect on left ventricular function or area at risk, a trend was observed towards a smaller infarct size as percentage of the area at risk in patients with first acute myocardial infarction who were to be treated with primary percutaneous coronary intervention [64]
What is the current research status of semaglutide for neurological conditions
